The place of pneumococcal vaccination

Drug and Therapeutics Bulletin

Volumn 36, Issue 10, 1998, Pages 73-76

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ASPLENIA; BACTEREMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; FEVER; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; INJECTION PAIN; INTRADERMAL DRUG ADMINISTRATION; MENINGITIS; META ANALYSIS; MYALGIA; REVACCINATION; SHORT SURVEY; STREPTOCOCCUS INFECTION; VACCINATION;

EID: 0031785349     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.1998.361073     Document Type: Short Survey

References (43)

1. UK Health Departments. Immunisation against infectious disease. HMSO, 1996
2. Hendley JO, Sande MA, Stewart PM, Gwaltney Jr JM. Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. J Infect Dis 1975; 132: 55-61.
3. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511-4.
4. MacFarlane J. The clinical impact of pneumococcal disease. In. The clinical impact of pneumococcal disease and strategies for its prevention. (Ed Mayon-White RT).Royal Society of Medicine International Congress and Symposium Series 210. London 1995; 9-17.
5. Laurichesse H, Grimaud O, Waight P, Johnson AP, George RC, Miller E. Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. Commun Dis and Public Health 1998; 1: 22-7
6. Watanakunakorn C, Greifenstein A, Stroh K et al. Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989. Chest 1993; 103: 1152-6.
7. Aszkenasy OM, George RC, Begg NT. Pneumococcal bacteraemia and meningitis in England and Wales 1982 to 1992. Commun Dis Rep CDR Rev 1995; 5: R45-50.
8. Sims RV, Boyko EJ, Maislin G, Lipsky BA, Sanford Schwartz J. The role of age in susceptibility to pneumococcal infections. Age Ageing 1992; 21: 357-61.
9. Urwin G, Yuan MF, Hall LMC, Brown K, Efstratiou A, Feldman RA. Pneumococcal meningitis in the North East Thames Region UK: epidemiology and molecular analysis of isolates. Epidemiol Infect 1996; 117: 95-102.
10. Waghorn DJ, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed? J Infect 1997; 35: 289-94.
11. Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in Southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 1996; 174: 752-9.
12. Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986; 146: 2179-85.
13. Marfin AA, Sporrer J, Moore PS, Siefkin AD. Risk factors for adverse outcomes in persons with pneumococcal pneumonia. Chest 1995; 107: 457-62.
14. Koivula I, Sten M, Mäkelä PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313-20
15. Afessa B, Greaves WL, Frederick WR. Pneumococcal bacteremia in adults: a 14-year experience in an inner-city university hospital. Clin Infect Dis 1995; 21: 345-51.
16. Steven N, Wright P. Pneumococcal immunisation and the healthy elderly. Lancet 1992; 340: 1036-7.
17. Johnson AP, Speller DCE, George RC, Warner M, Domingue G, Efrastiou A. Prevalence of antibiotic resistance and serotypes in pneumococci in England and Wales: results of observational surveys in 1990 and 1995. BMJ 1996; 312: 1454-6.
18. M 18. Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77.
19. R 19. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-90.
20. R 20. Örtqvist A, Hedlund J, Burman L-Å et al and Swedish Pneumococcal Vaccination Study Group. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998; 351: 399-403.
21. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425-30.
22. Farr BM, Lynn Johnston B, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk. Arch Intern Med 1995; 155: 2336-40.
23. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Sanford Schwartz J. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988; 108: 653-7.
24. Shapiro ED, Clements JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-30.
25. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-60.
26. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-31.
27. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176: 100-4.
28. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer Jr EA (Eds). Vaccines Second edition. Philadelphia: Saunders, 1994.
29. Grimfors G, Söderqvist M, Holm G, Lefvert AK, Björkholm M. A longitudinal study of class and subclass antibody response to pneumococcal vaccination in splenectomized individuals with special reference to patients with Hodgkin's disease. Eur J Haematol 1990; 45: 101-8.
30. Molrine DC, George S, Tarbell N et al. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease Ann Intern Med 1995; 123: 828-34.
31. Avanzini MA, Carra AM, Maccario R et al Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J Clin Immunol 1995; 15: 137-144.
32. Parkkali T, Käyhty H, Ruutu T, Volin L, Eskola J, Ruutu P. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 1996; 18: 961-7.
33. Glesby MJ. Immunizations during HIV infection. Curr Opin Infect Dis 1998; 11: 17-21.
34. Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 1997; 119: 167-74.
35. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. BMJ 1996; 312: 430-4.
36. McDonald P, Friedman EHI, Banks A, Anderson R, Carman V. Pneumococcal vaccine campaign based in general practice. BMJ 1997; 314: 1094-8.
37. Nichol KL, MacDonald R, Hauge M. Side effects associated with pneumococcal vaccination. Am J Infect Control 1997; 25 223-8.
38. Pnu-Imune. Summary of product characteristics, UK. Wyeth Laboratories, January 1997
39. Fuchshuber A, Kühnemund O, Keuth B, Lütticken R, Michalk D, Querfeld U Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996; 11: 468-73.
40. Rodriguez R, Dyer PD. Safety of pneumococcal revaccination. J Gen Intern Med 1995; 10: 511-2.
41. Sisk JE, Moskowitz AJ, Whang W et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-9
42. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-96. Clin Infect Dis 1998; 26: 1117-23.
43. Honkanen PO, Keistinen T, Kivelä S-L. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. Vaccine 1997; 15: 317-20.